{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:08:35Z","timestamp":1771859315819,"version":"3.50.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR203338"],"award-info":[{"award-number":["NIHR203338"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Human T-lymphotropic virus (HTLV) is associated with adult T-cell leukemia\/lymphoma and myelopathy. Here we present virological and epidemiological data on HTLV screening of blood donations in England between 2002 and 2021, implemented to prevent its transmission via blood transfusion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data on HTLV testing of blood donations was reviewed; it was initially conducted in pools (2002\u20132012) and subsequently using individual samples (all donors, 2013\u20132016; first-time donors and non-leucodepleted component donors, 2017\u20132021). Data included annual number of donations screened, initial and repeat reactives as well as confirmed positives. Further information, such as likely source of infection, was obtained for HTLV-positives.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Over the 20-year study period, a total of 30 679 741 blood donations were screened for HTLV in England. Under pooled screening strategy, the annual rate of repeat reactive donations remained &amp;lt;5:100 000. However, this rate increased to 51:100 000 with individual screening and further to 123:100 000 with selective screening. A total of 5032 samples were repeat reactive, of which 278 were confirmed HTLV-positives. Although the specificity under each scenario exceeded 99.9%, the rate of repeat reactives was around 50-fold higher in individual compared to pooled screening. Most HTLV infected were UK-born, most likely acquired their infection unknowingly through breast feeding or heterosexual intercourse with an individual associated with an HTLV-endemic country.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data highlight that pooled testing can be advantageous in low-prevalence settings due to its high specificity and reduced non-specific reactivity. Whether pooling is an applicable strategy to tackle the burden of HTLV infection in resource-poor, HTLV-endemic countries requires further investigations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaf053","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T15:17:00Z","timestamp":1738163820000},"page":"206-212","source":"Crossref","is-referenced-by-count":3,"title":["Human T-Lymphotropic Virus Screening of Blood Donations in England Between 2002 and 2021\u2014Comparison of Screening Strategies"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-4190","authenticated-orcid":false,"given":"Heli","family":"Harvala","sequence":"first","affiliation":[{"name":"Microbiology Services, NHS Blood and Transplant (NHSBT) , London ,","place":["United Kingdom"]},{"name":"Radcliffe Department of Medicine, University of Oxford , Oxford ,","place":["United Kingdom"]},{"name":"Infection and Immunity Unit, Institute of Biomedicine, Faculty of Medicine, University of Turku , Turku ,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6337-892X","authenticated-orcid":false,"given":"Katy","family":"Davison","sequence":"additional","affiliation":[{"name":"NHSBT and UK Health Security Agency (UKHSA) Epidemiology Unit, UKHSA , London ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8564-2893","authenticated-orcid":false,"given":"Mhairi","family":"Webster","sequence":"additional","affiliation":[{"name":"Microbiology Services, NHS Blood and Transplant (NHSBT) , London ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3452-0832","authenticated-orcid":false,"given":"Claire","family":"Reynolds","sequence":"additional","affiliation":[{"name":"NHSBT and UKHSA Epidemiology Unit, NHSBT , London ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3773-2390","authenticated-orcid":false,"given":"Graham P","family":"Taylor","sequence":"additional","affiliation":[{"name":"Section of Virology, Department of Infectious Disease, Faculty of Medicine, Imperial College London , London ,","place":["United Kingdom"]},{"name":"National Centre for Human Retrovirology, Imperial College Healthcare NHS Trust, St Mary's Hospital , London ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"2025080104323122700_ciaf053-B1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/rmv.1980030304","article-title":"The epidemiology of human T-lymphotropic virus types I and II","volume":"3","author":"Kaplan","year":"1993","journal-title":"Rev Med Virol"},{"key":"2025080104323122700_ciaf053-B2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00042560-199802010-00011","article-title":"Incidence of HTLV-I-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) in Jamaica and Trinidad","volume":"17","author":"Maloney","year":"1998","journal-title":"Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"2025080104323122700_ciaf053-B3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/BF03165123","article-title":"Human T lymphotropic virus type-I and adult T-cell leukemia in Japan","volume":"76","author":"Yamaguchi","year":"2002","journal-title":"Int J Hematol"},{"key":"2025080104323122700_ciaf053-B4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ijc.2910430214","article-title":"Modelling the risk of adult T-cell leukemia\/lymphoma in persons infected with human T-lymphotropic virus type I","volume":"43","author":"Murphy","year":"1989","journal-title":"Int J Cancer"},{"key":"2025080104323122700_ciaf053-B5","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/S2666-5247(21)00330-X","article-title":"Health inequities and HTLV-1","volume":"3","author":"Rosadas","year":"2022","journal-title":"Lancet Microbe"},{"key":"2025080104323122700_ciaf053-B6","volume-title":"Human T-lymphotropic virus type 1: technical report","author":"World Health Organization","year":"2021"},{"key":"2025080104323122700_ciaf053-B7","volume-title":"Geographical distribution of areas with a high prevalence of HTLV-1 infection","author":"European Centre for Disease Control (ECDC)","year":"2015"},{"key":"2025080104323122700_ciaf053-B8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/00002030-199306000-00013","article-title":"Seroepidemiology of HTLV-I\/II in universal screening of blood donations in France","volume":"7","author":"Courouc\u00e9","year":"1993","journal-title":"AIDS"},{"key":"2025080104323122700_ciaf053-B9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00126334-200501010-00018","article-title":"The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women","volume":"v38","author":"Taylor","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025080104323122700_ciaf053-B10","first-page":"R65","article-title":"Surveillance of HTLV infection in England and Wales: 1986\u20131992","volume":"4","author":"Simms","year":"1994","journal-title":"Commun Dis Rep CDR Rev"},{"key":"2025080104323122700_ciaf053-B11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-3148.2008.00902.x","article-title":"The introduction of anti-HTLV testing of blood donations and the risk of transfusion transmitted HTLV, UK: 2002\u20132006","volume":"19","author":"Davison","year":"2009","journal-title":"Transfus Med"},{"key":"2025080104323122700_ciaf053-B12","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/bmj.320.7248.1497","article-title":"Human T cell leukaemia\/lymphoma virus infection in pregnant women in the United Kingdom: population study","volume":"320","author":"Ades","year":"2000","journal-title":"BMJ"},{"key":"2025080104323122700_ciaf053-B13","doi-asserted-by":"crossref","first-page":"20017","DOI":"10.2807\/ese.16.46.20017-en","article-title":"Recruiting individuals into the HTLV cohort study in the United Kingdom: clinical findings and challenges in the first six years, 2003 to 2009","volume":"16","author":"Brant","year":"2011","journal-title":"Euro Surveill"},{"key":"2025080104323122700_ciaf053-B14","doi-asserted-by":"crossref","first-page":"30539","DOI":"10.2807\/1560-7917.ES.2017.22.20.30539","article-title":"Human T-lymphotropic viruses (HTLV) in England and Wales, 2004 to 2013: testing and diagnoses","volume":"22","author":"Ireland","year":"2017","journal-title":"Euro Surveill"},{"key":"2025080104323122700_ciaf053-B15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/tme.12482","article-title":"Interpretation of low reactivity in the Abbott Architect rHTLV I\/II assay","volume":"28","author":"Tosswill","year":"2018","journal-title":"Transfus Med"},{"key":"2025080104323122700_ciaf053-B16","volume-title":"Options for human T-cell lymphotropic virus (HTLV) screening within the UK blood services","author":"UK Blood Transfusion Services Joint Professional Advisory Committee's (JPAC) HTLV Working Group","year":"2015"},{"key":"2025080104323122700_ciaf053-B17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/tme.12576","article-title":"Safe supplies: few infections in UK blood and tissue donors","volume":"29","author":"Reynolds","year":"2019","journal-title":"Transfus Med"},{"key":"2025080104323122700_ciaf053-B18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3201\/eid2504.180984","article-title":"Self-flagellation as possible route of human T-cell lymphotropic virus type-1 transmission","volume":"25","author":"Tang","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2025080104323122700_ciaf053-B19","volume-title":"Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030","author":"World Health Organization","year":"2022"},{"key":"2025080104323122700_ciaf053-B20","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/trf.12105","article-title":"Human T-lymphotropic virus lookback in NHS blood and transplant (England) reveals the efficacy of leukoreduction","volume":"53","author":"Hewitt","year":"2013","journal-title":"Transfusion"},{"key":"2025080104323122700_ciaf053-B21","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/jcm.27.8.1893-1895.1989","article-title":"Sensitivity and specificity of pooled versus individual sera in a human immunodeficiency virus antibody prevalence study","volume":"27","author":"Cahoon-Young","year":"1989","journal-title":"J Clin Microbiol"},{"key":"2025080104323122700_ciaf053-B22","volume-title":"Laboratory diagnosis of HIV infection","author":"UK Standards for Microbiology Investigations","year":"2023"},{"key":"2025080104323122700_ciaf053-B23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/tme.12866","article-title":"Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T-cell leukaemia virus type-1 and type-2 infection in a London teaching hospital with a large solid organ transplant centre","volume":"32","author":"Lee","year":"2022","journal-title":"Transfus Med"},{"key":"2025080104323122700_ciaf053-B24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/vox.13577","article-title":"The importance of confirmatory assays in testing blood donors for human T-cell lymphotropic virus","volume":"119","author":"Martins","year":"2024","journal-title":"Vox Sang"},{"key":"2025080104323122700_ciaf053-B25","volume-title":"Screening donated blood for transfusion-transmissible infections: recommendations","author":"World Health Organization","year":"2009"},{"key":"2025080104323122700_ciaf053-B26","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3201\/eid2809.220487","article-title":"Fulminant transfusion-associated hepatitis E virus infection despite screening, England, 2016\u20132020","volume":"28","author":"Harvala","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2025080104323122700_ciaf053-B27","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.2020.5445","article-title":"Sample pooling as a strategy to detect community transmission of SARS-CoV-2","volume":"323","author":"Hogan","year":"2020","journal-title":"JAMA"},{"key":"2025080104323122700_ciaf053-B28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/vox.13617","article-title":"An international review of the characteristics of viral nucleic acid-amplification testing (NAT) reveals a trend towards the use of smaller pool sizes and individual donation NAT","volume":"119","author":"Faddy","year":"2024","journal-title":"Vox Sang"},{"key":"2025080104323122700_ciaf053-B29","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/bmj.307.6914.1235","article-title":"Prevalence of antibodies to human T cell leukaemia\/lymphoma virus in blood donors in north London","volume":"307","author":"Brennan","year":"1993","journal-title":"BMJ"},{"key":"2025080104323122700_ciaf053-B30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1590\/S0036-46652007000600005","article-title":"Performances of HTLV serological tests in diagnosing HTLV infection in high-risk population of S\u00e3o Paulo, Brazil","volume":"49","author":"Jacob","year":"2007","journal-title":"Rev Inst Med Trop Sao Paulo"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf053\/61738439\/ciaf053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/1\/206\/61738439\/ciaf053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/1\/206\/61738439\/ciaf053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T08:33:40Z","timestamp":1754037220000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/1\/206\/7997035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,3]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf053","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,15]]},"published":{"date-parts":[[2025,2,3]]}}}